AbbVie announced the launch of PRODUODOPA® in the EU for the treatment of advanced Parkinson’s disease with severe motor fluctuations and hyperkinesia or dyskinesia, and when available combinations of Parkinson’s medicinal products have not given satisfactory results.
PRODUODOPA is the first-and-only subcutaneous 24-hour infusion of levodopa-based therapy for the treatment of severe motor fluctuations in people living with advanced Parkinson’s disease whose symptoms are inadequately controlled by other therapies.
Parkinson’s disease is a chronic, progressive neurodegenerative disorder affecting approximately 6.1 million people globally and is expected to double by 2040.
“People living with Parkinson’s disease experience daily challenges and uncertainty, especially as their disease progresses and symptoms are no longer adequately controlled,” said Roopal Thakkar, Senior Vice President, Development and Regulatory Affairs and Chief Medical Officer, AbbVie. “This approval is an example of our unwavering commitment to this community by developing new, transformative therapeutic options for people experiencing advanced Parkinson’s disease, their families, and care partners.”
“This approval represents a significant advancement for those with Parkinson’s disease who have historically had limited treatment options for advanced stages,” said Angelo Antonini, MD, PhD, Professor of Neurology at the Department of Neuroscience, University of Padua (Università degli Studi di Padova), Italy. “When oral treatment no longer sufficiently helps with improvement in motor fluctuations, patients need alternative options. PRODUODOPA’s around-the-clock infusion allows for continuous delivery of levodopa, the gold standard of treatment.”
“As Parkinson’s progresses, it can take a significant physical and emotional toll not only on the person but also on their family and care partners, who often play a critical role in their daily lives,” said Josefa Domingos, President, Parkinson’s Europe. “It is vital that the Parkinson’s community have more options that can help them manage their symptoms.”
👉 AbbVie Launches PRODUODOPA® (foslevodopa/foscarbidopa) for People Living with Advanced Parkinson’s Disease in the European Union – Jan 9, 2024 (abbvie.com)
